# EDGAR Filing Document

**Accession Number:** 0001314102
**File Stem:** 0001193125-25-310731
**Filing Date:** 2025-12
**Character Count:** 9167
**Document Hash:** 7856ca81560d3f54f4afbf130d623413
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-310731.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001193125-25-310731

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251208

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EyePoint Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001314102
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 262774444
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51122
- **FILM NUMBER:** 251554864

**BUSINESS ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-926-5000

**MAIL ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida Corp.
- **DATE OF NAME CHANGE:** 20080619

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida LTD
- **DATE OF NAME CHANGE:** 20050111

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): December 8, 2025

## EyePoint Pharmaceuticals, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-51122** | **26-2774444** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **480 Pleasant Street** |  |
| **Watertown, Massachusetts** | **02472** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (617) 926-5000

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.001 | EYPT | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.03** | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**  |

---

On December 8, 2025, EyePoint, Inc. (the "Company") filed a certificate of amendment (the "Certificate of Amendment") to its Certificate of Incorporation, as amended, solely to change the Company's name from "EyePoint Pharmaceuticals, Inc." to "EyePoint, Inc." The name change became effective on December 8, 2025. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

In connection with the name change, the Company's Board of Directors approved an amendment (the "By-laws Amendment") to the Company's by-laws, as amended (the "By-laws"), to reflect the change in the Company's name, also effective December 8, 2025. No other changes were made to the By-laws. A copy of the By-laws Amendment is attached as Exhibit 3.2 hereto and is incorporated herein by reference.

The Company's common stock continues to trade on the Nasdaq Global Market under the ticker symbol "EYPT."

The name change does not affect the rights of the Company's security holders, and the CUSIP number for Company's common stock will continue to be 30233G209.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 3.1 | [Certificate of Amendment to Certificate of Incorporation.](d60563dex31.htm) |
| 3.2 | [Amendment No. 2 to the By-Laws.](d60563dex32.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **EyePoint Pharmaceuticals, Inc.** |
| Date: December 8, 2025 | By: | /s/ George O. Elston |
|  |  | George O. Elston |
|  |  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 3.1

Exhibit 3.1

**CERTIFICATE OF AMENDMENT TO THE** 

**CERTIFICATE OF INCORPORATION** 

**OF** 

**EYEPOINT PHARMACEUTICALS, INC.** 

EyePoint Pharmaceuticals, Inc. (the "<u>Corporation</u>"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "<u>DGCL</u>"), for the purpose of amending its Certificate of Incorporation, as amended (the "<u>Certificate of Incorporation</u>"), in accordance with the DGCL, does hereby make and execute this Certificate of Amendment to the Certificate of Incorporation, and does hereby certify that:

1. That the Board of Directors of the Corporation, by the unanimous written consent of its members, adopted
resolutions setting forth the proposed amendment to the Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders in accordance with the provisions of
Section 242 of the DGCL. The resolution setting forth the proposed amendment is as follows:

**RESOLVED**, that the first section of the Certificate of Incorporation of the Corporation be amended in its entirety as follows:

"The name of this corporation is EyePoint, Inc."

2. The Certificate of Amendment to the Certificate of Incorporation has been duly adopted and approved by the
Board of Directors in accordance with the provisions of Section 242 of the DGCL

3. That except as amended hereby, the provisions of the Certificate of Incorporation, shall remain in full force
and effect.

4. This Certificate of Amendment to the Certificate of Incorporation shall be effective as of December 8,
2025. [*Remainder of Page Intentionally Blank*]

------

IN WITNESS WHEREOF, I have signed this Certificate of Amendment this 8<sup>th</sup> day of December, 2025.

---

| | |
|:---|:---|
| **EYEPOINT PHARMACEUTICALS, INC.** | **EYEPOINT PHARMACEUTICALS, INC.** |
| By: | /s/ Ron Honig |
| Name: | Ron Honig |
| Title: | Chief Legal Officer |

---

*[Signature Page to Certificate of Amendment]*

## Exhibit 3.2

Exhibit 3.2

**AMENDMENT NO. 2 TO** 

**BY-LAWS** 

**OF** 

**EYEPOINT PHARMACEUTICALS, INC.** 

THIS AMENDMENT NO. 2 TO THE BY-LAWS OF EYEPOINT PHARMACEUTICALS, INC. (this "<u>Amendment</u>") is authorized, approved and adopted effective as of December 8, 2025 (the "<u>Effective Date</u>").

WHEREAS, the Board of Directors (the "<u>Board</u>") of EyePoint Pharmaceuticals, Inc., a Delaware corporation (the "<u>Company</u>"), which possesses the authority to amend the By-laws of the Company (the "<u>By-laws</u>") pursuant to Section 12.1 of such By-laws and Article 8 of the Company's Certificate of Incorporation, as amended, has authorized, approved and adopted the following Amendment to the By-laws, effective as of the Effective Date:

1. The title of the By-laws is hereby amended and restated in its entirety as follows:

"By-Laws of EyePoint, Inc."

------

**IN WITNESS WHEREOF**, EyePoint Pharmaceuticals, Inc. has caused this Amendment to be signed by Ron Honig, the duly authorized Secretary of the Corporation, as of the date first written above.

---

| | |
|:---|:---|
| By: | /s/ Ron Honig |
| Name: | Ron Honig |
| Title: | Chief Legal Officer |

---

*[Signature Page to By-laws Amendment]*